Back

Capturing SARS-CoV-2 immune landscapes to inform future strategies for COVID-19 vaccination in a high-income setting: a mathematical modelling study

Hogan, A. B.; Muscatello, D. J.; Liu, B.; Nedjati-Gilani, G.; Wood, J. G.

2025-03-19 public and global health
10.1101/2025.03.18.25324222 medRxiv
Show abstract

BackgroundIn an era of endemic SARS-CoV-2 transmission, countries are continuing to evaluate how best to schedule ongoing COVID-19 booster vaccinations. Mathematical modelling provides a useful tool to predict the benefit of future vaccination strategies, incorporating the loss of protection due to waning immunity and strain mutation. MethodsWe adapted a combined immunological-population transmission model for SARS-CoV-2, to better capture contemporary understanding of exposure- and vaccine-derived immunity, to simulate ongoing endemic transmission of SARS-CoV-2 in a highly exposed high-income setting. We used this model to estimate the impact of targeted booster dose strategies in the older population, both in the context of continued circulation of the current dominant viral strain, and in the presence of a new antigenically distinct variant. ResultsWe found that at the population level, an annual COVID-19 vaccine booster dose to the 65+ years population at 60% coverage could avert 10-17% of hospitalisations over a single wave, depending on how well-matched the vaccine is to the circulating SARS-CoV-2 strain. With lower coverage of 40%, estimated impact was between 9-12%. A second booster dose to the 75+ population after 6 months was particularly beneficial if a new distinct variant strain increases the magnitude of the wave. ConclusionsThis adapted model captures endemic viral transmission and could readily be used to explore vaccine impact across other settings.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

1
BMC Medicine
163 papers in training set
Top 0.1%
25.6%
2
The Lancet Infectious Diseases
71 papers in training set
Top 0.2%
9.1%
3
The Journal of Infectious Diseases
182 papers in training set
Top 0.6%
4.8%
4
BMJ Open
554 papers in training set
Top 5%
4.2%
5
Vaccine
189 papers in training set
Top 0.8%
3.7%
6
PLOS Medicine
98 papers in training set
Top 1%
3.6%
50% of probability mass above
7
PLOS Computational Biology
1633 papers in training set
Top 12%
2.6%
8
JAMA Network Open
127 papers in training set
Top 1%
2.6%
9
American Journal of Epidemiology
57 papers in training set
Top 0.5%
2.4%
10
BMC Public Health
147 papers in training set
Top 2%
2.4%
11
Annals of Internal Medicine
27 papers in training set
Top 0.3%
2.1%
12
JMIR Public Health and Surveillance
45 papers in training set
Top 1%
2.1%
13
Clinical Infectious Diseases
231 papers in training set
Top 2%
2.1%
14
BMC Infectious Diseases
118 papers in training set
Top 2%
1.9%
15
The Lancet
16 papers in training set
Top 0.2%
1.9%
16
Vaccines
196 papers in training set
Top 1%
1.7%
17
The Lancet Regional Health - Europe
32 papers in training set
Top 0.1%
1.7%
18
Nature Communications
4913 papers in training set
Top 51%
1.7%
19
EClinicalMedicine
21 papers in training set
Top 0.4%
1.3%
20
PLOS ONE
4510 papers in training set
Top 60%
1.2%
21
The Lancet Public Health
20 papers in training set
Top 0.4%
1.2%
22
The Lancet Regional Health - Western Pacific
15 papers in training set
Top 0.2%
0.9%
23
Nature Medicine
117 papers in training set
Top 4%
0.9%
24
The Lancet Global Health
24 papers in training set
Top 1%
0.8%
25
Frontiers in Public Health
140 papers in training set
Top 8%
0.8%
26
Scientific Reports
3102 papers in training set
Top 73%
0.8%
27
Journal of The Royal Society Interface
189 papers in training set
Top 5%
0.7%
28
BMJ Global Health
98 papers in training set
Top 3%
0.7%
29
Journal of Virology
456 papers in training set
Top 4%
0.7%
30
npj Vaccines
62 papers in training set
Top 0.5%
0.7%